pharmaceuticals
S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. 
Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA.
Issues related to drug pricing and transparency, generally.
Issues related to the importation of prescription medicines Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP).
ASP, generally
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs 
Medicare Part D, including removal of safe harbor protection for drug rebates
Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program
PHA - Pharmacy MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
900 G Street NW, Suite 301, Washington, DC, 20001, US
STEVEN E IRIZARRY VINCENT A. ROBERTI, SR. STEVEN E IRIZARRY VINCENT A. ROBERTI, SR.